Barchart.com
[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist Watchlist | Portfolio Portfolio | Dashboard Dashboard
Hi,
Site News
Contact
Market:
Your Free 7-Day Premier trial ends on . Extend Your Trial For Another 30 Days. Time remaining
News Menu

News

Oncternal Therapeutics Announces the Sale of Select Development Programs and the Wind-Down of its Operations

GlobeNewswire - Press Release

All information and data in this article is solely for informational purposes. For more information please view the Barchart Disclosure Policy here
Follow us on Google News Follow us on Google News

SAN DIEGO, July 01, 2025 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. today announced the sale of its zilovertamab and ONCT-808 programs to Ho’ola Therapeutics, Inc. Zilovertamab is an investigational monoclonal antibody designed to inhibit the function of Receptor Tyrosine Kinase-Like Orphan Receptor 1 (ROR1), and ONCT-808 is an investigational autologous chimeric antigen receptor T (CAR T) cell therapy that targets ROR1 using the binding domain from zilovertamab.

Read more at globenewswire.com

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.

Related Symbols

Symbol Last Chg %Chg
ONCT 0.5266 -0.1673 -24.11%
Oncternal Therapeutics Inc

Most Popular News

Microsoft sign at the headquarters by VDB Photos via Shutterstock 1
MSFT Stock Alert: Moonshot Could Give Microsoft Another AI Revenue Stream
Trader at NYSE by Orhan Akkurt via Shutterstock 2
S&P Futures Tread Water Ahead of Warsh’s Jackson Hole Speech; Marvell Sinks After Earnings
Apple Inc logo on Apple store-by PhillDanze via iStock 3
Is Apple Stock Outperforming the S&P 500?
A concept image of a cancer cell 3dMediSphere via Shutterstock 4
Forget Nvidia. Johnson & Johnson and 2 Other AI Stocks Are Beating the Market by 29 Points.
OPTIONS TRADING open book on table by One Photo via Shutterstock 5
BAC, CHWY, SONY: Play Unusual Options Activity in These 3 Low-Cost Call Options Under $100
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.